In summary, our meta-analysis has demonstrated that PD-1/ PD-L1 inhibitors including nivolumab, pembrolizumab and atezolizumab could increase the risk of all-grade pneumonitis rather than CTLA4 inhibitor (ipilimumab). Here, CTLA4 is linked to pneumonitis.